uniQure to Post FY2027 Earnings of $0.67 Per Share, HC Wainwright Forecasts (NASDAQ:QURE)

uniQure (NASDAQ:QURE) – HC Wainwright cut their FY2027 earnings estimates for uniQure in a research report issued on Wednesday, May 8th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings of $0.67 per share for the year, down from their prior forecast of $0.68. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($4.49) per share. HC Wainwright also issued estimates for uniQure’s FY2028 earnings at $2.74 EPS.

A number of other research firms also recently issued reports on QURE. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Friday, March 1st. The Goldman Sachs Group downgraded shares of uniQure from a “buy” rating to a “neutral” rating and cut their price target for the company from $63.00 to $8.00 in a research report on Thursday, February 29th. Mizuho cut their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 price target on shares of uniQure in a research report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.91.

uniQure Stock Performance

uniQure stock traded down $0.10 on Friday, hitting $4.97. The company’s stock had a trading volume of 145,703 shares, compared to its average volume of 914,777. The firm has a market cap of $237.75 million, a P/E ratio of -0.78 and a beta of 0.98. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49. The company has a fifty day moving average price of $4.98 and a 200-day moving average price of $5.88. uniQure has a one year low of $4.25 and a one year high of $22.48.

uniQure (NASDAQ:QURE) last announced its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.01. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. The business had revenue of $6.69 million for the quarter, compared to analyst estimates of $3.20 million.

Institutional Trading of uniQure

A number of large investors have recently modified their holdings of the business. Raymond James & Associates raised its holdings in shares of uniQure by 220.1% during the 3rd quarter. Raymond James & Associates now owns 49,079 shares of the biotechnology company’s stock valued at $329,000 after buying an additional 33,746 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of uniQure by 12.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 214,686 shares of the biotechnology company’s stock valued at $1,441,000 after buying an additional 23,997 shares in the last quarter. CTC Alternative Strategies Ltd. purchased a new position in uniQure in the 3rd quarter worth approximately $87,000. Diamond Hill Capital Management Inc. purchased a new position in uniQure in the 3rd quarter worth approximately $167,000. Finally, Privium Fund Management B.V. increased its stake in uniQure by 6.5% in the 3rd quarter. Privium Fund Management B.V. now owns 281,606 shares of the biotechnology company’s stock worth $1,890,000 after purchasing an additional 17,268 shares during the period. Institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling

In other uniQure news, COO Pierre Caloz sold 9,455 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at $554,110.21. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Matthew C. Kapusta sold 27,904 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.35, for a total transaction of $177,190.40. Following the completion of the sale, the chief executive officer now owns 440,839 shares in the company, valued at $2,799,327.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the transaction, the chief operating officer now owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The disclosure for this sale can be found here. Insiders have sold a total of 53,265 shares of company stock valued at $339,845 over the last ninety days. 4.74% of the stock is owned by company insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.